Bing Zhao's questions to I-Mab (IMAB) leadership • H1 2023
Question
Bing Zhao asked how the potential approval of Astellas' zolbetuximab might impact the clinical plan for givastomig and questioned the rationale for selecting a 4-1BB bispecific target over others.
Answer
CMO John Hayslip and President Andrew Zhu highlighted givastomig's differentiation, citing its efficacy across a broad range of Claudin expression levels and a more favorable safety profile with less GI toxicity than competing monoclonal antibodies. This positions it strongly for the first-line setting. The 4-1BB target was chosen for its ability to conditionally activate the immune system within the tumor microenvironment, thereby minimizing systemic side effects.